Introduction
============

The central nervous system (CNS) has been considered for many years as an organ immunologically isolated from the peripheral immune system, on one hand due to the presence of the blood brain barrier (BBB) and the absence of lymphatic vessels ([@B113]) and, on the other hand, by the fact that skin grafts and the direct inoculation of viruses, bacteria or antigens in the nervous parenchyma did not induce an immune response ([@B103]; [@B11]; [@B151]; [@B98]). Nevertheless, in the last decade, an increasing number of studies has demonstrated that the CNS is not only immune-competent, but it also actively interacts with cells of the peripheral immune system ([@B6]; [@B14]; [@B150]; [@B3]; [@B59]), which can be recruited to the nervous parenchyma under specific circumstances ([@B127]; [@B48]; [@B12]; [@B46], [@B47]).

With all of these studies in mind, it is easy to think that the isolated view of the CNS has drastically changed toward a more active scenario, in which a situation of active immune tolerance is continuously maintained within the CNS. Different mechanisms have been reported to contribute to this active tolerance, including the constitutive expression of FasL, a receptor involved in the death of infiltrated immune cells ([@B15]; [@B52]) and the local production of anti-inflammatory mediators such as indolamine 2,3-dioxygenase, in response to the interaction with pro-inflammatory lymphocytes ([@B87]). The presence of some populations of cells, such as macrophages and dendritic cells (DCs), located in strategic areas of the CNS such as the meninges and the choroid plexus, may play a key function in the initiation and regulation of immune responses. Nowadays, then, the CNS is considered as an immune-privileged site, rather than immune-isolated ([@B112]; [@B126]).

Infiltration of Lymphocytes in the CNS Under Pathological Situations
====================================================================

The infiltration of lymphocytes within the CNS parenchyma is a common hallmark in many pathological conditions ([@B132]; [@B8]) such as VIH ([@B114]) and West Nile virus infection ([@B57]); neurodegenerative diseases such as Parkinson's disease ([@B21]) and amyotrophic lateral sclerosis ([@B68]); acute lesions like facial nerve axotomy ([@B124]), entorhinal cortex lesion ([@B10]), stroke ([@B140]; [@B53]) and ischemia ([@B53]) or autoimmune processes such as experimental autoimmune encephalomyelitis ([@B41]; [@B2]). While in some circumstances lymphocyte infiltration has been related to protective functions, as occurs in the facial nerve axotomy paradigm ([@B146]), the West Nile virus infection ([@B57]) and amyotrophic lateral sclerosis ([@B17]; [@B29]), in other circumstances lymphocyte infiltration has been shown to contribute to the exacerbation of the pathology. This is the case of Parkinson's disease ([@B21]), VIH virus infection ([@B114]), stroke ([@B172]) and some autoimmune diseases ([@B41]).

Due to the fact that T-cells are not able to recognize soluble antigens, they need the help of specialized cells, the so-called antigen presenting cells (APCs), which through antigen presentation mechanisms can capture, process and present pathogen and viral antigens and other strange structures for recognition by T-cells. Depending on the pattern of cytokine secretion, the functions and the molecules that drive their differentiation, different subtypes of T-helper lymphocytes are identified ([@B129]; [@B157]; [@B155]). Classical classification considers two different subtypes: T-helper 1 (Th1) lymphocytes, which secrete pro-inflammatory cytokines such as interferon-γ (IFN-γ) or tumoral necrosis factor-α (TNF-α) and Th2 lymphocytes, which produce anti-inflammatory cytokines such as interleukin-4 (IL-4) and interleukin-10 (IL-10). Therefore, Th1 accumulation has been usually considered as an inflammatory event, whereas presence of Th2 has been related to the down-regulation of the inflammatory response. However, a growing accumulation of evidence has changed this simple paradigm based on the presence/absence of Th1/Th2, as other subpopulations of Th cells have been discovered, among them, effector T-cells including Th17, Th22, Th9, T-follicular helper (Tfh) cells with the capacity to secrete different cytokines ([@B31]), but also regulatory T-cells such as T-regulatory (Treg) and Tr1, whose principal function is to maintain the immune system homeostasis and the tolerance to self-antigens ([@B18]; [@B45]; [@B116]). Two different subtypes of Treg are currently identified: the natural Treg (nTreg) and the induced Treg (iTreg) ([@B69]; [@B33]; [@B116]). The nTregs, defined as CD4+CD25+Foxp3+ cells, are generated in the thymus during the maturation of T-cells by recognition of self-peptides with intermediate affinity, whereas the iTregs are produced in secondary lymphoid organs (spleen and lymph nodes) from naïve CD4+Foxp3- T-cells under both homeostatic conditions and in the presence of inflammation, infection or allergy after stimulation with TGF-β ([@B116]). Due to their capacity to suppress immune responses, the participation of Tregs in the evolution of acquired immune responses in the CNS, especially those related to autoimmunity, has generated much attention in the last several years. In this sense a remarkable accumulation of Tregs in cerebral gliomas ([@B61]), ischemic stroke ([@B154]) and in some experimental models of encephalomyelitis such as EAE ([@B99]; [@B83]; [@B84]) has been reported.

The discovery of all of these subtypes of lymphocytes with putative new functions in the promotion and modulation of the acquired immune response and their still-unknown interactions with resident CNS cells, specially microglia, has contributed to becoming aware that the scenario of the neuroimmune response could be even more complicated than previously thought.

Activated Microglia are Considered the Main APC in the CNS
==========================================================

Microglial cells are considered the sole representative of the immune system within the CNS parenchyma. The precise origin of microglia during development still remains under debate, although emerging evidence reported that yolk-salk primitive precursors are the principal source ([@B55], [@B56]; [@B141]). Studies in bone-marrow chimera and parabiotic mice indicated that these yolk-salk precursors invade the CNS parenchyma through the blood vessels around embryonic Day 9 in mice, corresponding to the vascularization process, and contribute substantially to the maintenance of microglial cells in the adult ([@B55]). However, alternative routes of entry for microglial precursors, including the ventricles and meninges, have been identified ([@B32]; [@B35], [@B36]; [@B105]). Whether these different routes of entry are linked to different populations of microglial precursors with different functions is an interesting field that is still unsolved.

Microglial cells are equipped with a broad range of receptors in their plasma membrane that allows them to sense subtle changes in the micro-environment ([@B78]; [@B64]; [@B79]). Microglial cells play very important roles in healthy, normal CNS, not only during the post-natal period, where they contribute to the elimination of synaptic structures ([@B119]; [@B163]; [@B65]), but also in the adult, where they are continuously scanning their local micro-environment ([@B37]; [@B108]; [@B79]; [@B25]). When the homeostasis of the CNS is perturbed as a result of injury or disease, microglial cells become rapidly activated, acquiring a specific phenotype totally dependent on the environment in which they are activated and the specific stimulus that drives their activation ([@B78]; [@B59]; [@B28]). Activated microglia can rapidly proliferate and increase the expression or *de novo* express a multitude of different molecules and secrete a plethora of substances such as cytokines, chemokines and trophic factors, all of which make them able to modulate both the innate and the acquired immune responses within the CNS ([@B125]; [@B78]; [@B44]; [@B58]; [@B24]).

Recognition of the T-cell receptor (TCR) on the surface of T-lymphocytes by the major histocompatibility complexes (MHCs) located on the surface of the APCs, MHC-I in the case of CD8+T-cytotoxic lymphocytes and MHC-II for CD4+T-helper cells, constitutes the first signal of the antigen-presenting mechanism related to the activation of T-cells ([@B90]; [@B1]). Co-stimulation, the second signal involved in this mechanism, is based on the binding of diverse receptors and counter-receptors expressed on the surface of both APC and T-cells ([@B109]) and is essential for a complete antigen presentation, as expression of MHCs in the absence of co-stimulation leads to the apoptosis or anergy of T-cells ([@B82]). A multitude of co-stimulatory pairs of molecules, which can be classified into two main families (the B7/CD28 and the TNFR families), have been reported in the immune system, exerting different effects on the activation/deactivation of T-cells ([@B147]) and driving the final outcome and function of T-cells.

Expression of MHCs in Microglia
-------------------------------

Resident glial cells, principally microglia, can establish a cross-talk with infiltrated T-cells regulating their recruitment, activation and function within the CNS ([@B59]). Although in healthy CNS microglial cells do not express MHCs ([@B86]; [@B113]), it is well known that, when activated in pathological conditions, they showed a wide number of phenotypic changes ([@B125]; [@B78]; [@B120]), including *de novo* expression of these molecules ([@B86]; [@B113]). Therefore, many authors consider microglial cells as the principal APC within the CNS parenchyma ([@B5]; [@B23]; [@B123]; [@B60]). Expression of MHC-II in activated microglia *in vivo* has been reported after a wide variety of CNS injuries including LPS injection ([@B171]; [@B107]), ischemia and kainic acid injection ([@B50]), graft *vs.* host disease ([@B142]), facial nerve axotomy ([@B153]; [@B166]), entorhinal cortex lesion ([@B16]; [@B88]) and different models of EAE ([@B4]).

Expression of Co-stimulatory Molecules in Microglia
---------------------------------------------------

While the expression of MHCs has been extensively reported in activated microglia, only a limited number of studies have addressed the question of whether activated MHC-II+ microglia simultaneously express co-stimulatory molecules (Summarized in **Table [1](#T1){ref-type="table"}**).

###### 

Principal co-stimulatory molecules from the B7/CD28 and TNFR family.

  -----------------------------------------------------------------------------------------------------------------------------------
                   Effect on T-cell   T-cell    APC             Determined in microglia   Experimental model        Reference
  ---------------- ------------------ --------- --------------- ------------------------- ------------------------- -----------------
  B7/CD28 family                                                                          PPT                       [@B16]\
                                                                                                                    [@B89]

                   Stimulation        CD28                                                                          

                                                                                          Peripheral nerve injury   [@B134]

                                                                                                                    

                                                                                          FNA                       [@B20]

                                                                                                                    

                                                B7.1/B7.2       \+                        Cuprizone                 [@B130]

                                                                                                                    

                   \                  \                                                   \                         [@B73]\
                   \                  \                                                   \                         [@B75]\
                   Inhibition         CTLA-4                                              EAE models                [@B95]\
                                                                                                                    [@B123]\
                                                                                                                    [@B4]\
                                                                                                                    [@B3]

                                                                                                                    

                   Stimulation        ICOS      B7H2 (ICOS-L)   n.d.                      --                        --

                                                                                                                    

                                                                                          MCAO                      [@B131]\
                                                                                                                    [@B19]

                                                                                                                    

                                                                                          Coronavirus infection     [@B115]

                                                                                                                    

                                                                                          TMEV                      [@B43]\
                                                                                                                    [@B74]

                   Inhibition         PD-1      B7H1 (PD-L1)    \+                                                  

                                                                                          EAE models                [@B139]

                                                                                                                    

                                                                                          PPT                       [@B93]

                                                                                                                    

                                                B7DC (PD-L2)    n.d.                      --                        --

                                                                                                                    

                   Inhibition         TLT-2     B7H3            n.d.                      --                        --

                                                                                                                    

                   Inhibition         Unknown   B7H4            n.d.                      --                        --

                                                                                                                    

                   Inhibition         Unknown   B7S3            n.d.                      --                        --

                                                                                                                    

                   Inhibition         Unknown   BTNL            n.d.                      --                        --

                                                                                                                    

  TNFR family                                                                             \                         [@B160]\
                                                                                          \                         [@B122]\
                                                                                          Microglial cultures       [@B91]\
                                                                                                                    [@B92]\
                                                                                                                    [@B165]

                                                                                                                    

                                                                                          Ageing                    [@B62]\
                                                                                                                    [@B149]

                                                                                                                    

                                                                                          Epilepsy                  [@B156]

                                                                                                                    

                                                                                          Alzheimer's disease       [@B161]\
                                                                                                                    [@B162]\
                                                                                                                    [@B158]

                   Stimulation        CD40-L    CD40            \+                                                  

                                                                                          ALS                       [@B110]

                                                                                                                    

                                                                                          Neurodegeneration         [@B77]

                                                                                                                    

                                                                                          HIV infection             [@B39], [@B38]

                                                                                                                    

                                                                                          EAE models                [@B13]; [@B118]

                                                                                                                    

                                                                                          TMEV                      [@B111]

                                                                                                                    

                                                                                          MS                        [@B167]

                                                                                                                    

                   Stimulation        OX40      OX40-L          n.d.                      --                        --

                                                                                                                    

                   Stimulation        CD27      CD70            n.d.                      --                        --
  -----------------------------------------------------------------------------------------------------------------------------------

The table summarized the different molecules studied in the context of microglial cells (+). n.d indicates that the expression has not been determined specifically in microglia. PPT, perforant pathway transection; FNA, facial nerve axotomy; EAE, experimental autoimmune encephalomyelitis; MCAO, middle cerebral artery occlusion; TMEV, Theiler's induced encephalitis; ALS, amyotrophic lateral sclerosis; MS, multiple sclerosis.

### The B7/CD28 Family

The pair of co-stimulatory molecules with the major relevance in the activation of T-cells, and therefore the most extensively studied in the organism, is that formed by receptors B7.1/B7.2 (CD80/CD86) on the surface of APCs and their counter-receptors CD28 and CTLA-4 on the surface of T-cells. The binding of B7.1 or B7.2 to CD28 induces T-cell proliferation and cytokine secretion, whereas binding of these same receptors to CTLA-4 induces the inhibition of T-cell activity, promoting the down-regulation of the immune response ([@B136]; [@B148]). Specifically in the CNS, *de novo* expression of B7.1 and/or B7.2 has been reported in microglial cells after entorhinal cortex lesion ([@B16]; [@B89]), peripheral nerve injury ([@B134]), facial nerve axotomy ([@B20]), cuprizone-induced demyelination ([@B130]) and models of autoimmunity such as EAE and Theiler's virus encephalomyelitis ([@B73]; [@B75]; [@B95]; [@B123]; [@B4], [@B3]).

Recently, other members of the B7 co-stimulatory molecules family have been described in the immune system, including B7-H2 (ICOS-L), B7-H1 (PD-L1), B7-DC (PD-L2), B7H3 (CD276), B7H4, B7S3 and BTNL ([@B147]; [@B27]). The ICOS-ICOSL pathway has important roles in the fine-tuning of effector T-cell functions and the control of T-cell tolerance ([@B109]). Although the presence of ICOS+ T-cells has been reported in the CNS of EAE-induced mice ([@B133]), to-date, no studies on the expression of its ICOSL ligand on microglia or any other CNS resident cells are available. PD-1 is another receptor gaining attention, due to its crucial role in maintaining peripheral immune tolerance ([@B109]). PD-1 has been shown to be a negative regulator of T-cell responses, expressed at low levels on the surface of T, B and natural killer T-cells, and further induced upon activation. PD-1 has two counter-receptors that are expressed on the surface of APCs, PD-L1 and PD-L2 also called B7H1 and B7DC, respectively ([@B109]). The few reports addressing the expression of this molecule in the CNS demonstrated PD-L1 expression in both activated microglia after middle-cerebral artery occlusion ([@B131]; [@B19]), coronavirus infection ([@B115]), Theiler's murine encephalomyelitis ([@B43]; [@B74]) and EAE ([@B139]), and in astrocytes after entorhinal cortex lesion ([@B93]). Moreover, the blockade of PD-1 signaling enhances EAE severity ([@B135]) suggesting an outstanding role in the control of CNS pathologies.

To our knowledge, no studies regarding the expression of B7H3, B7H4, B7S3 or BTNL specifically in microglia are, until present, available in the literature.

### The TNFR Family

Additionally, a second family of co-stimulatory receptors, the TNFR family, has been reported in the immune system. Various members, including pairs CD40/CD40L, OX40L/OX40, and CD70/CD27, expressed on APCs and T-cells, respectively, form this family ([@B169]; [@B147]). Among them, CD40 is the only molecule studied in the context of microglial activation ([@B26]). CD40 expression in activated microglia has been described not only *in vitro* in many cell-lines activated with IFN-γ, LPS or β-amyloid protein ([@B160]; [@B122]; [@B92]; [@B91]; [@B165]) but also *in vivo* during physiological aging ([@B62]; [@B149]) and under pathological situations such as epilepsy ([@B156]), Alzheimer's disease ([@B161]; [@B162]; [@B159]), amyotrophic lateral sclerosis ([@B110]), neurodegeneration induced by thiamine deficiency ([@B77]), human HIV ([@B39], [@B38]), different animal models of autoimmunity such as EAE ([@B13]; [@B118]) and Theiler's murine encephalomyelitis ([@B111]) and MS ([@B167]). Moreover, inhibition of CD40 in microglia results in the attenuation of β-amyloid pathology ([@B158]) and the reduction of EAE severity ([@B13]; [@B118]), pointing toward this molecule as a good candidate for therapeutic interventions in these specific CNS pathologies.

Altogether, these studies indicate that, although so far it seems that microglial cells may be the principal APC within the CNS, in the coming years it will be necessary to inquire about the expression of some other markers related to the antigen-presenting mechanism described in professional DCs and, until now, not explored in the context of microglial activation.

Other Molecules Expressed by Microglia that can be Involved in the Communication with T-Cells
=============================================================================================

Recent studies indicate that CD39 and CD73, some of the molecules that mediate the immunosuppressive activity of Treg lymphocytes ([@B40]), are also expressed in specific subtypes of APCs and may be involved in the suppressive activity of these cells. Specifically, a subtype of DCs induced by IL27 has been shown to increase expression of CD39 and exert protective functions in EAE ([@B96]). CD39 and CD73 (also known as NDPase and 5′ nucleotidase, respectively) are enzymes involved in the hydrolysis of extracellular ATP to ADP/AMP and to adenosine. CD39-deficiency in DCs has been shown to ameliorate the course of EAE by reducing the number of Th1 and Th17 effector cells ([@B96]). The precise mechanism by which CD39 regulates T-cell responses is not clear, although it is proposed to be mediated by a reduction in the ATP levels producing a down-regulation of the inflammasome activity ([@B45]), a multiprotein-assembled complex involved in the initiation of the immune innate responses ([@B164]).

Expression of both CD39 and CD73 in the membrane of microglial cells has been extensively reported to regulate ATP levels within the CNS, in both healthy situations and after damage ([@B25]). Therefore, it is easy to suggest that regulation of the expression of those enzymes in activated microglia take part in modulating the final outcome of infiltrated T-cells.

Presence of Dendritic Cells in the CNS
======================================

Dendritic cells are considered to be the professional APCs in the immune system ([@B63]). They are derived from hematopoietic stem cells in the bone marrow that gives rise to early precursors called the Common Myeloid Precursor (CMP). CMPs, in turn, originate the formation of two different precursors, the Granulocyte/Monocyte precursors (G/Ms) and the Macrophage/DC precursors (M/DPs). From M/DPs, the common DC progenitors, the pre-DC precursors and the plasmacytoid DCs are sequentially formed. Pre-DC precursors egress into the blood circulation and populate different organs, including the skin, heart, lung and spleen, becoming conventional DCs ([@B94]). As both DCs and macrophages derived from the same precursors most of the markers and functions of these two populations are similar.

Although the parenchyma of the normal CNS are devoid of the so-called professional DCs, these cells are abundant in the meninges, the choroid plexus ([@B101]; [@B102]), the perivascular space and the juxtavascular parenchyma (i.e., the neuropil just beyond the glia limitants) ([@B121]). These locations are considered strategically well-positioned for the communication with blood-circulating pathogens or T-cells, supporting a role of DCs in the control of the entry gates to the brain and thus in the regulation of immune surveillance in the CNS during homeostasis. With aging, the number of DCs increases markedly in the perivascular space, meninges and choroid plexuses, and has even been found into the brain parenchyma ([@B152]; [@B76]). The presence of CNS parenchymal DCs has also been reported in different neuroinflammatory situations ([@B100]; [@B30]; [@B34]), including infections ([@B51]), traumatic brain injury ([@B72]), ischemia ([@B85]; [@B128]; [@B49]; [@B53]), excitotoxicity ([@B106]) and some diseases such as amyotrophic lateral sclerosis ([@B66]), multiple sclerosis ([@B117]; [@B144]) and EAE ([@B97]; [@B143]; [@B51]; [@B137]; [@B138]; [@B4], [@B3]).

Function of DCS in the CNS
==========================

Numerous works ([@B100]; [@B30]; [@B34]) emphasize the possible relevance of DCs in the CNS immunosurveillance as well as the function they can play in neuroinflammatory situations. However, the specific contribution of those cells is still not well-understood.

The actual knowledge regarding the function of DCs in the brain come from studies using the inoculation of different types of DCs into the CNS under different circumstances. Thus, it has been shown that subcutaneous administration of bone marrow DCs before EAE-induction prevents EAE development in rats ([@B70]). Other studies reported that intraparenchymal inoculation of tolerogenic DCs, induced by TNF-α treatment, prevents or delays EAE onset, whereas immunogenic DCs administration increases the severity of this disease ([@B174]).

All together, these studies have demonstrated the potential of DCs to serve as potent vehicles to induce tolerance and open a door to new therapeutic strategies to modulate CNS disease. A question not yet addressed in this kind of studies is how these DCs interact with both glial cells and blood--borne infiltrated cells. Research in this field in the coming years is vital to understand the molecular and cellular mechanisms involved in the regulation of immune responses in the CNS.

Are CNS Parenchymal DCS Authentic DCS or are they a Subtype of Activated Microglia?
===================================================================================

In addition to the poor knowledge on the role of DCs in the immune responses within the CNS, one of the issues that generate more controversy is the origin of parenchymal DCs observed in a wide range of neuroinflammatory situations (**Figure [1](#F1){ref-type="fig"}**). One possibility suggested by some authors is that the perivascular or meningeal DCs observed in the healthy brain are recruited to inflammatory sites within the CNS parenchyma ([@B100]). Alternatively, other authors supported the idea that parenchymal DCs observed during neuroinflammatory conditions come from infiltrated monocytes ([@B71]), which under the influence of specific molecules such as GM-CSF, differentiate to DCs ([@B9]). Supporting this idea, an alternative developmental circuit occurring after the MDP precursors involves monocytes as precursors of inflammatory DCs in peripheral organs ([@B42]; [@B94]). Infiltration of monocytes is a common event in many of the above-mentioned neuroinflammatory situations in which DCs have been described in the CNS parenchyma ([@B173]; [@B145]; [@B104]). Furthermore, systemic administration of GM-CSF in EAE-induced mice mobilizes Ly6C^high^-circulating monocytes that migrate to the CNS parenchyma and are converted into DCs ([@B80]). Nevertheless, later studies have demonstrated that intraparenchymal infusion of GM-CSF not only promotes the apparition of DC precursors recruited from the periphery but also induces the emergence of a second population of DCs derived from the CNS with an inhibitory phenotype ([@B67]), supporting the idea that DCs not only immigrate from the periphery but may also be derived from local CNS cells.

![**Putative origins of parenchymal dendritic cells during neuroinflammatory conditions.** In the CNS, under steady-state conditions a population of professional DCs expressing MHC-class II and CD11c or ED2 are found in the meninges, the choroid plexuses and the perivascular space, where they coexist with specific subpopulations of resident macrophages (Mø). Under specific neuroinflammatory conditions, such as infections, traumatic brain injury or EAE, DCs have been also reported within the CNS parenchyma. Different possibilities are suggested to explain the origin of these parenchymal DCs (green arrows). The first possibility (1) is that parenchymal DCs are derived from activated microglia. The second possibility (2) is that parenchymal DCs come from the recruitment of either perivascular or meningeal or both DC populations. The third possibility (3) is that DCs come from infiltrated monocytes (Ly6C^high^). Recent research indicates that parenchymal DCs are constituted by two different populations of cells, one becoming from microglia and the other infiltrated from the periphery. Although both populations of parenchymal DCs present the ability to activate T-cells, the fact that they display a distinct phenotype, characterized principally by changes in the levels of CD45 and the pattern of cytokine secretion, suggest that they may play different roles in the regulation of the immune response.](fncel-09-00440-g001){#F1}

In this regard, several lines of evidence, including *in vitro* studies ([@B51]; [@B22]) and neuroinflammatory situations such as ischemia ([@B85]) and EAE ([@B51]; [@B3]; [@B170]), support the hypothesis that parenchymal DCs are derived from the differentiation of local cells, probably microglia, on the basis that the expression of some of the surface antigens commonly used for the identification of DCs, such as CD11c, MHCII and CD86, are found in activated microglial cells. In addition, a study using the CD11c-GFP mouse, which expresses the GFP protein under the control of the CD11c promoter, the pan-marker of DCs, has reported the presence of CD11c+ cells not only in the choroid plexuses and perivascular space but also in the juxtavascular parenchyma of non-lesioned CNS ([@B121]). Interestingly, these authors found that almost all CD11c+ cells in the juxtavascular parenchyma presented markers of microglial cells such as Iba1 and CD11b, indicating that, presumably, a subpopulation of microglial cells is able to express DC markers in steady-state conditions. Even more, an interesting study ([@B7]) using the Flt3-treatment, a transcription factor involved in the generation of DCs ([@B168]; [@B81]), to induce the expansion of DCs in transgenic mice carrying the EYFP fluorescent protein under the control of the CD11c promoter, demonstrated the presence of two different populations of CD11c+ cells within healthy CNS. These two populations corresponded to a population of EYFP+ cells located in the choroid plexuses and meninges whose number increased after Flt3 treatment and another discrete population of EYFP+ cells located in CNS parenchyma with ramified morphology whose number remains stable after the treatment. Flow cytometry studies of these two populations demonstrated that the EYFP+ cells in the choroid plexuses and meninges presented a profile of CD45^high^/MHCII+ DCs, whereas those EYFP+ cells in the parenchyma corresponds to CD45^int^/MHCII- microglial cells ([@B7]). Furthermore, other works ([@B170]) using flow cytometry for different DCs markers have reported the existence of two populations of DCs in EAE-induced animals *in vivo*: CD11c+ DCs and CD11c+ microglia. Interestingly, both populations showed a similar ability to induce T-cell proliferation *in vitro* but, once activated, those T-cells showed a different cytokine profile, suggesting that both populations can play different functions in T-cell activation ([@B170]).

Altogether, these studies indicate, as previously suggested by other authors ([@B54]), that in addition to professional DCs located in meninges, choroid plexuses and the perivascular space, there is a population of microglial cells that, according to environmental cues, can acquire the phenotype of DCs and consequently may act as professional APCs. One issue to be resolved is if these parenchymal DCs that come from microglia develop the same functions as other DCs or, conversely, if both populations in the CNS have different roles regulating the immune response.

Concluding Remarks
==================

Current research suggests that the net effect of the acquired immune response within the CNS must depend not only on the number of lymphocytes and APCs, but must also be directly related to the specific subtype of infiltrated lymphocytes, the particular phenotype of the APC in each situation and the specific micro-environment in which the communication between these two cells takes place. Whether the principal intercomunicators in the cross talk with T-cells are microglial cells, professional DCs or both is an intriguing question, still under discussion, and should be subject to thorough investigation. Research to help clarify the question of the origin and a more complete characterization of the phenotype and function of parenchymal DCs in CNS will offer a more comprehensive understanding of the role played by these cells during the evolution of neuroinflammatory processes.
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